Mallinckrodt Inc. Completes Acquisition of CNS Therapeutics, Inc.

Published: Oct 02, 2012

HAZELWOOD, Mo.--(BUSINESS WIRE)--Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE: COV), today announced that it has completed its acquisition of CNS Therapeutics, Inc. for approximately $100 million. CNS is a privately held specialty pharmaceuticals company focused on developing and commercializing products for site-specific administration to the central nervous system to treat neurological disorders and intractable chronic pain.

Back to news